MG
TRAW icon

Mather Group’s Traws Pharma TRAW Stock Holding History

Mather Group’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-96
Closed -$2.42K – 2247
2024
Q2 		$2.42K Buy
+96
New +$1.55K ﹤0.01% 1836

Other funds holding TRAW

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VWWMG
Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $174M AUM 15.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Mather Group's TRAW Position: Q3 2024 in Review

Mather Group sold out of Traws Pharma (TRAW) in Q3 2024, closing a stake of 96 shares — an estimated $2.42K sold.

Mather Group first reported a position in TRAW in Q2 2024 and held it in 1 quarter. The position peaked at $2.42K in Q2 2024. 12 funds tracked by Wall St. Rank hold TRAW as of Q3 2024.

  • Mather Group reported no remaining Traws Pharma position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 96 Traws Pharma shares in Q3 2024, an estimated $2.42K.
  • Mather Group first reported a position in Traws Pharma in Q2 2024 and held it in 1 quarter.
  • Mather Group's Traws Pharma position peaked at $2.42K in Q2 2024.
  • 12 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.